Jasper Therapeutics (JSPR) Change in Accured Expenses (2020 - 2025)

Jasper Therapeutics' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$4.1 million for Q4 2025.

• In Q4 2025, Change in Accured Expenses fell 323.6% year-over-year to -$4.1 million; the TTM figure through Dec 2025 stood at -$4.4 million (down 251.93% YoY), while the FY2025 annual figure was -$4.4 million, down 251.93% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at -$4.1 million, down from -$700000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.3 million in Q2 2023, with the low at -$4.1 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $193500.0 (2021), against an average of $156050.0.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses soared 38500.0% in 2022, then plunged 441.19% in 2023.
• Jasper Therapeutics' Change in Accured Expenses stood at -$2.1 million in 2021, then soared by 145.81% to $968000.0 in 2022, then sank by 143.8% to -$424000.0 in 2023, then surged by 528.77% to $1.8 million in 2024, then plunged by 323.6% to -$4.1 million in 2025.
• Business Quant data shows JSPR's Change in Accured Expenses at -$4.1 million in Q4 2025, -$700000.0 in Q3 2025, and $3.0 million in Q2 2025.